Vertex And NHS England To Do 'More Talking’ This Week On Reimbursing Orkambi
Vertex Pharmaceuticals and NHS England are due to meet this week to see whether they can resolve their pricing deadlock over the cystic fibrosis drug Orkambi. Meanwhile, UK ministers are urging the company to bring these negotiations to an urgent resolution.
You may also be interested in...
Dialogue between Vertex and NHS England over cystic fibrosis drug Orkambi are set to continue after productive talks on April 25.
Vertex and NHS England are under pressure to strike a deal on cystic fibrosis drug Orkambi after UK a parliamentary debate put health technology appraisal body NICE under the spotlight.
Despite an initial rejection from NHS England, Vertex remains committed to bringing its novel reimbursement plan to England to secure access to its cystic fibrosis drug, Orkambi.